Expression, Microbiome Features Provide Pre-Treatment Lung Function Clues for Pediatric Patients
By LabMedica International staff writers Posted on 15 Mar 2022 |
Microbial community and host gene expression features in lung samples may provide pre-treatment clues to risky lung function features in children receiving bone marrow transplants from healthy donor individuals.
Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pre-transplant lung function has hindered the development of lung-targeted interventions.
Clinical Scientists at the University of California at San Francisco (San Francisco, CA, USA) and their colleagues used metatranscriptomic RNA sequencing to profile microbiome and host gene expression features in bronchoalveolar lavage samples collected from 104 children in the Netherlands in roughly the week or two leading up to their allogeneic HCT treatments, comparing those patterns with results from matched pulmonary function tests. Sample RNA was combined with control spike-in RNA and underwent reverse transcription, library preparation, and 125-nucleotide paired-end sequencing on a NovaSeq 6000 instrument (Illumina, San Diego, CA, USA) to a target depth of 40 million read pairs per sample.
Among the 54 children showing signs of pulmonary restriction, impaired oxygen diffusion, lung capacity, or other altered pulmonary functions based on Global Lung Index cutoff scores, the team saw an overrepresentation of Staphylococcus and other skin or nasal passage-related microbes, but lower-than-usual levels of commensal microbes that are typically detected in the supraglottic region of the throat.
Depletion of commensal supraglottic taxa, such as Haemophilus, and enrichment of nasal and skin taxa, such as Staphylococcus, in the bronchoalveolar lavage (BAL) microbiome were associated with worse measures of lung capacity and gas diffusion. In addition, BAL gene expression signatures of alveolar epithelial activation, epithelial-mesenchymal transition, and down-regulated immunity were associated with impaired lung capacity and diffusion, suggesting a post-injury profibrotic response. Detection of microbial depletion and abnormal epithelial gene expression in BAL enhanced the prognostic utility of pre-HCT pulmonary function tests for the outcome of post-HCT mortality.
Joseph DeRisi, PhD, a Molecular Biologist and a senior co-author of the study, said, “Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pre-transplant lung function has hindered the development of lung-targeted interventions.”
The authors concluded that among children preparing to undergo allogeneic HCT, pulmonary function testing abnormalities were common and consisted mostly of restriction and impaired diffusion. Abnormalities were associated with pulmonary microbiome depletion, profibrotic signaling, and post-HCT mortality. The study was published on March 9, 2022 in the journal Science Translational Medicine.
Related Links:
University of California at San Francisco
Illumina
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA